MedTrace Logo

Tanezumab in Osteoarthritis of the Knee

NCT00733902 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 697

Last updated 2021-03-22

Study results available
· View outcomes & findings →

Summary

Test the efficacy and safety of 3 doses in Osteoarthritis of the knee in patients.

Conditions

Interventions

BIOLOGICAL

tanezumab

IV tanezumab 10 mg at 1 dose every 8 weeks

BIOLOGICAL

tanezumab

IV tanezumab 5 mg at 1 dose every 8 weeks

BIOLOGICAL

tanezumab

IV tanezumab 2.5 mg at 1 dose every 8 weeks

BIOLOGICAL

Placebo

IV placebo to match tanezumab at 1 dose every 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-15
Primary Completion
2009-08-24
Completion
2010-01-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00733902 on ClinicalTrials.gov